Loading...
Guest User
Welcome! Please login.
| IPO Listing At | NSE SME |
| SME IPO Issue Type | Fixed Price Issue |
| Total Issue Size | ₹18.17 Cr |
| Reserved for Market Maker | ₹0.00 Cr |
| Net Issue Size | ₹18.17 Cr |
| Fresh Issue | ₹17.25 Cr |
| Face Value | ₹10 Per Equity Share |
| Issue Price | ₹61.00 per share |
| Discount | Retail: 0.00 |
| NSE Code | JFLLIFE |
| Registrar | Kfin Technologies Ltd. |
| Lead Managers | GYR Capital Advisors Pvt.Ltd. |
| Allotment Status |
| DRHP |
| RHP |
| Final Prospectus |
 ₹0 A/C OpeningFree MF ₹20F&O Trade ₹0Delivery 1Cr+Customers Open Free Account → |
 ₹0 A/C Opening₹0 AMC Trading Account ₹20F&O Trade ₹20Delivery FreeIPO Apply Open Free Account → |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 2,000 shares and in multiples thereof
Incorporated in 2010, JFL Life Sciences Limited is engaged in the business of manufacturing of pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets & Capsules (B-Lactam) solid oral dosage form and Tablet and capsules (general) Solid Oral Dosage Form and Oral rehydration solutions (ORS).
The company's sales strategy is to sell the products in bulk to pharmaceutical marketers and traders who in turn provide the channel for sales to customers. JFL Life Sciences Limited has a market presence in PAN India and JFL's products are supplied to 10 developed and developing countries throughout the World.
JFL Life Sciences Limited exports products to African, Middle Eastern, and CIS countries, mainly through merchant exporters. The company is registered with the MOH of Kenya, Nigeria, Yemen, Cambodia & Myanmar for manufacturing a particular product. Few of our products are also registered with Ukraine, Uzbekistan, and Kazakhstan (CIS countries) through merchants.
JFL has two manufacturing units (on lease) in Gujarat.
Competitive Strength :
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment of secured and unsecured loans | 7.50 |
| 2 | Funding the working capital requirements of the company | 6.00 |
| 3 | General Corporate Purposes | 4.27 |
| Period Ended | 28 Feb 2022 | 31 Mar 2021 | 31 Mar 2020 | 31 Aug 2019 |
|---|---|---|---|---|
| Assets | 36.63 | 29.01 | 24.33 | 16.15 |
| Total Income | 25.63 | 32.87 | 30.20 | 31.78 |
| Profit After Tax | 2.53 | 0.54 | 0.36 | 0.30 |
| NET Worth | 10.97 | 6.87 | 5.38 | 5.01 |
| Reserves and Surplus | 2.94 | 6.38 | 4.95 | 4.59 |
| Amount in ₹ Crore | ||||
| KPI | |
|---|---|
| RoNW | 7.89% |
| PAT Margin | 1.65% |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 0.89 | |
| P/E (x) | 26.52 | |
| Promoter Holding | 92.52% | 67.47% |
| Market Cap | ₹67.09 Cr. | |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Issue Management fees including Merchant Banking fees and Market Making fees, Underwriting fees and payment to other intermediaries such as Legal Advisors, Registrars and other out of pocket expenses | 0.29 |
| 2 | Advertising and Marketing Expenses | 0.02 |
| 3 | Fees payable to the to the Regulators including stock exchange(s) | 0.07 |
| 4 | Printing & Stationery, Distribution, Postage, etc. | 0.01 |
| 5 | Brokerage and selling commission | 0.01 |
| 6 | Other Expenses (Banker’s to the Issue, Auditor’s fees etc.) | 0.02 |
Last Updated on 13-May-2026 10:31:38
